Children with type 1 diabetes and comorbid autism have a glycemic profile that is similar to children with type 1 diabetes but without autism, despite fewer patients with autism using insulin pump therapy, according to findings published in Pediatric Diabetes.
“Individualized care is still important in diabetes management, as it is in all cases, but simply having autism does not necessarily need to be seen by providers as a barrier to implementation of technology and aiming for glycemic targets,” Shideh Majidi, MD, assistant professor in pediatric endocrinology at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Campus, told Endocrine Today. “Youth with [autism spectrum disorder] can successfully integrate technology into their diabetes care, and this study finds that technology use could result in better glycemic management compared to multiple daily insulin injections.”
In a retrospective chart review, Majidi and colleagues analyzed data from 30 children with comorbid diagnoses of autism and type 1 diabetes (28 boys; mean autism duration, 4.4 years), each matched by age, sex and race with three children with type 1 diabetes but without autism (n = 90), seen at the Barbara Davis Center in Colorado between June 2014 and June 2015 (mean age, 13 years; mean diabetes duration, 4.9 years). Researchers evaluated autism duration, diabetes duration, insulin regimen type, total daily insulin dose, use of continuous glucose monitoring and total number of diabetic ketoacidosis events reported. Glycemic control was assessed by HbA1c.
Researchers found that the prevalence of comorbid autism in the type 1 diabetes population at the Barbara Davis Center was 11.6 per 1,000, or 1.16%, which is comparable to the overall Colorado population (1.09%). There were no between-group differences in the average number of blood glucose checks per day; however, children with comorbid autism had a lower HbA1c when compared with the overall clinic population (8.16% vs. 8.86%; P = .0064). For children whose parents reported mild autism symptoms (n = 7), mean HbA1c was 8% and 28.6% used insulin pump therapy, according to researchers, whereas those whose parents reported moderate symptoms (n = 6) had a mean HbA1c of 8.7% and 33.3% used insulin pump therapy. Children with comorbid autism also had a lower mean daily insulin dose vs. controls with type 1 diabetes (mean, 40.8 U vs. 53 U; P = .005).
“This study found no increased prevalence of autism spectrum disorder in type 1 diabetes compared to the general population,” Majidi said. “The study’s findings also suggest that individuals with autism are capable of having the same glycemic control as those without autism.”
There were no between-group differences with respect to CGM use; however, patients with comorbid autism were less likely to use insulin pump therapy vs. controls (37% vs. 61%; P = .03). After insulin pump therapy initiation, the researchers noted that HbA1c slope changes increased more over time for controls vs. patients with comorbid autism (P = .01).
The researchers noted that the data suggest that children with type 1 diabetes and autism may benefit more from uptake of insulin pump therapy vs. controls, particularly during adolescence, when HbA1c tends to rise.
“Due to more routine daily activities and rigid thinking, [insulin pump therapy] could benefit patients with [autism spectrum disorder] through providing more customizable insulin profiles,” the researchers wrote. “It may be hard to predict how much a child with [autism spectrum disorder] may eat, due to decreased communication skills, so the [insulin pump therapy] regimen would allow caregivers to give additional insulin without another shot.”
The researchers wrote that longitudinal studies could confirm the benefit of insulin pump therapy in patients with type 1 diabetes and autism when compared with the overall type 1 diabetes population. – by Regina Schaffer
For more information:
Shideh Majidi, MD, can be reached at the Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, 1775 Aurora Ct, Aurora, CO 80045; email: email@example.com.
Disclosures: The authors report no relevant financial disclosures.